Core Viewpoint - Southwest Securities predicts that the revenue of Insilico Medicine (03696) will reach $0.59 billion, $1.55 billion, and $2.02 billion for the years 2025-2027, with corresponding price-to-sales (PS) ratios of 78x, 30x, and 23x. The company's AI platform innovation capability has been validated, and long-term development is promising as more pipeline assets enter clinical stages and external licensing opportunities arise. The report initiates coverage with a recommendation for active attention [1]. Group 1: Core Competitiveness - The company's core competitiveness lies in its self-developed, globally leading end-to-end generative AI platform, Pharma.AI, which reduces the time from target discovery to clinical candidate confirmation from the industry average of 4.5 years to 12-18 months, validated through over 40 projects and 27 PCCs [2]. - The primary business model focuses on drug discovery and pipeline development, including external licensing, collaborative development, and independent development. Since 2026, the company has achieved three business development (BD) collaborations with upfront payments totaling $0.42 billion, and a total potential value of $10.74 billion. More BD collaborations are expected in 2026, potentially catalyzing stock price growth [1][3]. Group 2: Business Model - The company employs a dual-engine business model: 1) drug discovery and pipeline development through external licensing or collaborative development to obtain upfront payments, milestone payments, and sales shares; 2) software solutions generating subscription revenue from licensing the Pharma.AI platform. This model has been validated in the market, with nine external licensing agreements totaling over $4 billion in potential value and partnerships with 13 of the top 20 global pharmaceutical companies [3]. - The technology licensing generates cash flow and extensive validation data, while the success of internal pipelines further validates and enhances the AI platform's capabilities, creating a strong "data flywheel" effect [3]. Group 3: Pipeline and Product Potential - The company has nearly 20 clinical or IND application-stage assets generated from its platform, with the fastest pipeline, ISM001-055, being the world's first fully AI-discovered and designed candidate drug that has completed Phase IIa clinical trials for treating idiopathic pulmonary fibrosis (IPF). Recent clinical results show that patients receiving treatment exhibited dose-dependent improvements in lung function, with a significant difference of 118.7 milliliters compared to the placebo group [4]. - The IPF market presents substantial opportunities, and if ISM001-055 successfully reaches the market, it could become a disruptive therapy [4].